CHMP recommends EU approval of Roche ’s Hemlibra for people with haemophilia A with inhibitors

Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news